Join our journey
We welcome any and all commercial Next-Generation Sequencing players into our ecosystem. We believe that through out-licensing we can achieve an impact in this scattered market.
With strength in numbers we can achieve our mutual goals — enabling consistently accurate and fast diagnostics results for a fraction of the current cost.
We are actively looking for global level technology partnerships within liquid biopsy, infectious diseases (Covid19), NIPT, tropical diseases, antibiotic resistance – among others.
info <at> genomill.com
+358 (0)400 107 400